Study Finds Effective Methods for Smoking Cessation

Aug.30.2022
Study Finds Effective Methods for Smoking Cessation
A study found that varenicline, bupropion, and low-dose e-cigarettes were the most effective smoking cessation methods.

A study titled "Pharmacological and e-cigarette intervention for smoking cessation: systematic review, network meta-analysis, and cost-effectiveness analysis" was conducted by researchers at the University of Bristol in the UK. They searched a publication database up to March 2017 and updated their search in February 2019 with randomized clinical trials of smoking cessation interventions lasting for over six months.


The research team ultimately conducted a total of 363 experiments involving 201,045 participants. Additionally, they conducted 53 observational studies, which involved 8,783,5403 participants for safety review purposes.


After analyzing the results, the research team has concluded that the most effective treatment methods are substituting with Varencicline Standard plus Nicotine (odds ratio [OR], 3.22; 95% credible interval [CrI], 2.27-14.88), substituting with Varenicline Low plus Nicotine (OR, 5.70; 95% CrI, 1.57-21.12), and using low electronic cigarettes (OR, 3.22; 95% CrI, 0.97-12.55).


A controversial drug.


On October 1, 2021, the drug varenicline, commonly sold under the name Champix, was added to the World Health Organization's Essential Medicines List. This anti-smoking medication is well-known for helping smokers overcome cravings for cigarettes. However, despite being considered highly effective, it can also cause moderate to severe psychological side effects, ranging from terrifying nightmares to suicidal thoughts.


After multiple reports of such disturbances, the US Food and Drug Administration (FDA) issued the most severe warning for the drug, causing the sales of Valeni-cline to decrease from $846 million in 2008 to $671 million last year.


In order to overcome this decline, Pfizer, the manufacturer of the drug, has invested heavily in advertising and resolving lawsuits related to the medication. Additionally, the pharmaceutical company has released data retrieved from a study that allegedly proves that consuming Valenicline does not have a direct link to experiencing psychological disorders.


Subsequently, after refusing to lift the warning in 2014, the FDA recently decided to change their stance and abandon the warning. The agency has requested the listing of side effects associated with the drug, and has established a requirement that the label specify that varenicline is more effective than other smoking cessation therapies.


Vonnicron stock recall


Meanwhile, in June of last year, Pfizer was forced to halt distribution of Valsartan after discovering increased levels of nitrosamine in the pills and recalled some of its stock. However, in the following month, the US Food and Drug Administration announced that it would temporarily allow some manufacturers to distribute drugs containing carcinogens below a temporary limit of 185 nanograms per day until impurities could be eliminated or reduced to acceptable levels.


Disclaimer: 1. The content of this article is compiled from third-party information and is only intended for industry exchange and learning purposes. 2. This article does not represent the views of 2FIRSTS, and 2FIRSTS is unable to confirm the authenticity and accuracy of the content. The compilation of this article is only intended for industry exchange and research. 3. Due to the limitations of the compilation level, the compiled article may not express the same meaning as the original article. Please refer to the original article for accuracy. 4. For any domestic, Hong Kong, Macao, Taiwan, and foreign statements and positions, 2FIRSTS fully aligns with the Chinese government. 5. The copyright of the information compiled belongs to the original media and author. If there is any infringement, please contact us to delete it.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Sweden Threatens EU Tobacco Tax Deal as Nicotine Pouch Duty Dispute Looms Over November 9 Meeting
Sweden Threatens EU Tobacco Tax Deal as Nicotine Pouch Duty Dispute Looms Over November 9 Meeting
Sweden is expected to oppose a European Union proposal to raise minimum tobacco excise duties, Law360 reported on October 26, 2026, citing an EU official. A provisional Council agenda dated October 23 confirms that the tobacco taxation package is scheduled for discussion at the November 9 finance ministers' meeting, where member states will seek a general approach. The proposed reforms would raise minimum taxes on conventional tobacco products and establish EU-wide excise rules for vaping liquids, heated tobacco and nicotine pouches. Sweden supports harmonising tobacco taxation rules but objects to requiring nicotine pouches to bear the same minimum tax burden as certain smoking tobacco products. As EU indirect tax legislation requires unanimous Council approval, Swedish opposition could block the proposal in its current form.
Regulations
Oct.29
Product | KIWI Launches Spark 2 and Spark 2 Pro in Germany, Two Hardware Tiers Share Backward-Compatible 2ml Pods
Product | KIWI Launches Spark 2 and Spark 2 Pro in Germany, Two Hardware Tiers Share Backward-Compatible 2ml Pods
KIWI has launched the Spark 2 and Spark 2 Pro refillable pod systems in Germany at official prices of €18 and €29, respectively. Spark 2 uses an 800mAh removable lithium-ion battery in a pen-style body, while Spark 2 Pro features a 1,400mAh removable battery, a box-shaped design and vibration feedback every 20 puffs. Both devices use the same 2ml Spark V2 pods in 0.8Ω and 1.2Ω versions, with AirSync airflow adjustment and a choice between Cotton Tips and conventional Drip Tips. The new pods also remain compatible with the original KIWI Spark.
News
Sep.29 by 2Firsts Perspectives
On-Site Report | CTP Details PMTA Backlog, 180-Day Review Goal and sPMTA Process
On-Site Report | CTP Details PMTA Backlog, 180-Day Review Goal and sPMTA Process
FDA’s Center for Tobacco Products detailed new PMTA review data and process changes at the 2026 FDLI conference. Pending PMTAs fell from about 450,000 at the start of 2025 to 135,000 by September 2026. CTP also discussed its 180-day review goal, current sPMTA pilot, alternate-supplier planning, more than 50,300 pending SE reports, and lessons from the nicotine pouch pilot already being applied to ENDS review.
Regulations
Oct.07
Wisconsin Vape Directory One Year On: Retailer Reports Four Store Closures and 70% Staff Cuts
Wisconsin Vape Directory One Year On: Retailer Reports Four Store Closures and 70% Staff Cuts
Wisconsin's electronic vaping device directory has been fully enforced for more than a year, and local vape retailers say the reduced range of eligible products has contributed to declining sales, store closures and layoffs. Johnny Vapes owner Ben Hall said he has closed four of seven locations and cut about 70% of his staff. State law bars the sale of vaping devices not listed on the Wisconsin Department of Revenue directory and allows penalties of $1,000 per day for each unlisted device sold or offered for sale. In April 2026, the U.S. Court of Appeals for the Seventh Circuit allowed enforcement of the law to continue.
Regulations
Oct.10
Athletes Back Skoka's $21.5 Million Nicotine Pouch Venture: Can Its Consumer Health Founder Make an FDA-Focused Strategy Pay Off?
Athletes Back Skoka's $21.5 Million Nicotine Pouch Venture: Can Its Consumer Health Founder Make an FDA-Focused Strategy Pay Off?
U.S. nicotine pouch startup Skoka Inc. has raised $21.5 million and committed $15 million to an FDA regulatory and scientific research program. Founder Dan Aziz previously built dietary supplement brand Premama, which was acquired by Dr. Reddy's Laboratories in 2023. Skoka is combining proprietary formulations, ingredient transparency and equity investment from professional athletes. The company submitted a bundled PMTA covering 55 products on October 1, 2026. Aziz said Skoka declined an opportunity to enter retail in 2025, prioritizing product research and regulatory submissions instead. It now targets a U.S. retail launch in 2027, subject to FDA requirements. Its products have not received marketing authorization.
Business
Nov.04
Sweden Finds ZYN Ingredient Labels Noncompliant Over Generic Flavoring Disclosure, Swedish Match Faces SEK 2 Million Monthly Penalty
Sweden Finds ZYN Ingredient Labels Noncompliant Over Generic Flavoring Disclosure, Swedish Match Faces SEK 2 Million Monthly Penalty
Sweden's Public Health Agency has found ingredient labels on ZYN nicotine pouches sold by Philip Morris International subsidiary Swedish Match to be noncompliant, according to Dagens industri. The products' packaging listed 10 to 13 ingredients, compared with 11 to 42 in regulatory submissions, with multiple flavoring ingredients grouped under the generic term "aromer." The agency ordered corrective action, warning of a conditional penalty of SEK 2 million per month for noncompliance. The order applies only to products manufactured after the decision becomes legally effective and does not require recalls. Swedish Match disputes the agency's interpretation and plans to appeal.
PMI
Oct.22